Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Statins Improve Survival Rate In Trial, Could Strengthen OTC Platform

This article was originally published in The Tan Sheet

Executive Summary

Statin therapy in patients with systolic heart failure may improve survival without the need for "urgent" heart transplants, according to a study published in the Journal of the American College of Cardiology Feb. 18

You may also be interested in...



FDA Advisory committee schedule

FDA's Nonprescription Drugs Advisory Committee is slated for meetings in March and June, with specific dates to be announced, according to a tentative schedule of advisory committee meetings published in the Dec. 31 Federal Register. Possible overlaps with other committees may include the Endocrinologic & Metabolic Drugs Advisory Committee, slated to meet June 22-23, the Dermatologic & Ophthalmic Drugs Advisory Committee (June 24-25) and the Pulmonary-Allergy Drugs Advisory Committee, scheduled for June 29-30...

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS096516

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel